- Conditions
- SARS-CoV-2
- Interventions
- Upamostat, Placebo (PO)
- Drug
- Lead sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • Cleveland, Ohio • Nashville, Tennessee
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–3
of 3
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Covid19
- Interventions
- Part A: Upamostat 200 mg, Part A: Upamostat 400 mg, Part A and B: Placebo, Part B: Upamostat 200 or 400 mg
- Drug
- Lead sponsor
- RedHill Biopharma Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 11
- States / cities
- Cutler Bay, Florida • Hialeah, Florida • Miami, Florida + 7 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- WX-671, placebo
- Drug
- Lead sponsor
- Heidelberg Pharma AG
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 3
- States / cities
- New York, New York • Cleveland, Ohio • Philadelphia, Pennsylvania